ISIN | LU2041627865 |
---|---|
Valor Number | 49473285 |
Bloomberg Global ID | |
Fund Name | JSS Sustainable Equity - Future Health E USD acc |
Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
Fund Provider | J. Safra Sarasin Investmentfonds AG |
Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). |
Peculiarities |
Current Price * | 97.69 USD | 21.05.2025 |
---|---|---|
Previous Price * | 99.29 USD | 20.05.2025 |
52 Week High * | 111.03 USD | 30.08.2024 |
52 Week Low * | 90.83 USD | 08.04.2025 |
NAV * | 97.69 USD | 21.05.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 138,301,375 | |
Unit/Share Assets *** | 46,524 | |
Trading Information SIX |
YTD Performance | +0.07% |
31.12.2024 - 21.05.2025
31.12.2024 21.05.2025 |
---|---|---|
YTD Performance (in CHF) | -9.02% |
31.12.2024 - 21.05.2025
31.12.2024 21.05.2025 |
1 month | +1.56% |
22.04.2025 - 21.05.2025
22.04.2025 21.05.2025 |
3 months | -5.26% |
21.02.2025 - 21.05.2025
21.02.2025 21.05.2025 |
6 months | -1.50% |
21.11.2024 - 21.05.2025
21.11.2024 21.05.2025 |
1 year | -6.00% |
21.05.2024 - 21.05.2025
21.05.2024 21.05.2025 |
2 years | -7.99% |
22.05.2023 - 21.05.2025
22.05.2023 21.05.2025 |
3 years | -6.80% |
23.05.2022 - 21.05.2025
23.05.2022 21.05.2025 |
5 years | -2.31% |
18.06.2020 - 21.05.2025
18.06.2020 21.05.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
UnitedHealth Group Inc | 9.27% | |
---|---|---|
Eli Lilly and Co | 6.74% | |
Sanofi SA | 6.60% | |
Danaher Corp | 6.30% | |
Gilead Sciences Inc | 5.20% | |
Intuitive Surgical Inc | 4.51% | |
Boston Scientific Corp | 4.22% | |
Johnson & Johnson | 4.17% | |
Novo Nordisk AS Class B | 3.87% | |
argenx SE | 3.71% | |
Last data update | 31.03.2025 |
TER | 1.60% |
---|---|
TER date | 31.10.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.80% |
Ongoing Charges *** | 1.58% |
SRRI ***
|
|
SRRI date *** | 30.04.2025 |